Sunlenca is a Oral Tablet, Film Coated in the Human Prescription Drug category. It is labeled and distributed by Gilead Sciences. The primary component is Lenacapavir Sodium.
| Product ID | 61958-3001_e2f725c8-d250-42e1-bb62-249cf99bcb28 | 
| NDC | 61958-3001 | 
| Product Type | Human Prescription Drug | 
| Proprietary Name | Sunlenca | 
| Generic Name | Lenacapavir Sodium | 
| Dosage Form | Tablet, Film Coated | 
| Route of Administration | ORAL | 
| Marketing Start Date | 2022-12-22 | 
| Marketing Category | NDA / | 
| Application Number | NDA215974 | 
| Labeler Name | Gilead Sciences | 
| Substance Name | LENACAPAVIR SODIUM | 
| Active Ingredient Strength | 300 mg/1 | 
| NDC Exclude Flag | N | 
| Listing Certified Through | 2024-12-31 | 
| Marketing Start Date | 2022-12-22 | 
| NDC Exclude Flag | N | 
| Sample Package? | N | 
| NDC | Brand Name | Generic Name | 
|---|---|---|
| 61958-3001 | Sunlenca | LENACAPAVIR SODIUM | 
| 61958-3002 | Sunlenca | LENACAPAVIR SODIUM | 
| Mark Image Registration | Serial | Company Trademark Application Date | 
|---|---|
|  SUNLENCA  88823358  not registered Live/Pending | Gilead Sciences Ireland UC 2020-03-05 |